Herzog Hospital provides comprehensive, multi-disciplinary and individualized care and treatment to individuals suffering from Alzheimer’s and Parkinson’s Diseases. The interdisciplinary staff develops an individual treatment plan for each patient, and is conducting ground breaking research in the field.
Prof. Uri Heresco Levy, Director of the Psychiatry Division at Herzog Hospital, in collaboration with Prof. Daniel Javitt of New York University, discovered that glutamatergic amino acids may represent a new type of treatment for diseases characterized by movement dysfunctions, such as tardive dyskinesia, Parkinson’s disease and Huntington Disease. This discovery was approved as a new patent of Herzog Hospital by the European Patent Office of the EU, the Canadian Patent office, the Israel patent office, and is patent pending in the United States. To date, the patent has been registered in 27 European countries. Prof. Heresco-Levy and his team continue their research program assessing the efficacy of this type of compounds in neuropsychiatric disorders.